Q3 EPS Estimates for OPKO Health Increased by Zacks Research

Posted by on Aug 19th, 2026

OPKO Health, Inc. (NASDAQ:OPK – Free Report) – Equities researchers at Zacks Research raised their Q3 2026 EPS estimates for shares of OPKO Health in a research note issued to investors on Monday, August 17th. Zacks Research analyst Team now forecasts that the biotechnology company will earn ($0.06) per share for the quarter, up from their prior forecast of ($0.07). The consensus estimate for OPKO Health’s current full-year earnings is ($0.24) per share. Zacks Research also issued estimates for OPKO Health’s FY2026 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.06) EPS and FY2028 earnings at ($0.23) EPS.

OPKO Health (NASDAQ:OPK – Get Free Report) last issued its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. The company had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.OPKO Health’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.19) earnings per share.

A number of other research analysts have also issued reports on the company. HC Wainwright restated a “buy” rating on shares of OPKO Health in a research report on Wednesday, July 29th. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. Finally, Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $1.55.

View Our Latest Research Report on OPKO Health

OPKO Health Price Performance

Shares of OPKO Health stock opened at $1.36 on Wednesday. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -15.11 and a beta of 1.51. OPKO Health has a twelve month low of $0.98 and a twelve month high of $1.73. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. The business’s 50 day simple moving average is $1.37 and its 200-day simple moving average is $1.27.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently modified their holdings of the company. OP Asset Management Ltd bought a new stake in shares of OPKO Health in the 1st quarter worth $1,257,000. First Trust Advisors LP bought a new position in OPKO Health during the first quarter valued at about $570,000. UBS Group AG grew its holdings in OPKO Health by 12.1% during the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 577,248 shares during the period. Comerica Bank raised its position in OPKO Health by 7.1% in the fourth quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 8,000 shares in the last quarter. Finally, State of Wyoming acquired a new stake in OPKO Health in the 1st quarter valued at about $190,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

Featured Articles

Earnings History and Estimates for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.